In recent years, the incidence of prostate cancer has risen sharply. In European and American countries, the incidence rate is as high as about 20-30%. In North America, prostate cancer has surpassed skin cancer as the most common cancer in men, ranking second in the cause of cancer deaths. The incidence of prostate cancer in my country also reaches or approaches that of European and American countries.

ACTL technology has developed rapidly and has achieved good results in the prevention and treatment of prostate cancer, showing a bright future. The T cells activated by ACTL technology selectively destroy prostate cells that cause cancerous PSA and PSMA abnormal expression, achieving the purpose of treatment.

     ACTL treatment has no damage, no toxic side effects, can retain the normal physiological function of the prostate, and overcome the complications and sequelae caused by traditional treatment.

     Treatment case

This is a case of advanced prostate cancer. After three months of ACTL treatment, the tumor disappeared in a large area, the patient's mental state was improved, and the quality of life was greatly improved. The target antigens for treatment are PSA and PSMA.

      After the occurrence of prostate cancer, the cost of treatment is extremely high. Traditional treatment methods have poor efficacy and high mortality. Therefore, interventional treatment of prostate hyperplasia, that is, preventive treatment, is an effective means to prevent fatal prostate cancer, and has been widely recognized by the academic community.